Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Catalyst Biosciences Inc (CBIO) today and set a price target of $35. The company’s shares opened today at $8.47, close to its 52-week low of $6.20.
Amusa wrote:
“We noted Catalyst may enter the GT space. In our 7 September 2018 research, we took the view, “only a fraction of [Catalyst’s] compounds (e.g. vs FVIIa or FIX) would need to be delivered to achieve therapeutic factor levels… Alternatively or additionally, delivery of lower doses of vector, due to the higher potency of the Catalyst-sourced transgene, could help mitigate immunogenicity issues seen in the GT space.” DalcA would of course need to fully resolve questions on immunogenicity to be part of a viable GT construct.”
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 14.3% and a 45.3% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Applied Genetic Technologies, and Logicbio Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Catalyst Biosciences Inc with a $29.50 average price target, implying a 248.3% upside from current levels. In a report released today, Oppenheimer also reiterated a Buy rating on the stock with a $24 price target.
See today’s analyst top recommended stocks >>
Based on Catalyst Biosciences Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $7.69 million. In comparison, last year the company had a GAAP net loss of $5.75 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel medicines to address hemophilia condition. Its product pipeline includes FVIIa for the treatment of hemophilia A or B with inhibitors, FIX for hemophilia B treatment, and FXa, which is a universal pro-coagulant.
